TxCell Receives EU Orphan Drug Designation for Col-Treg
News Dec 19, 2014
TxCell SA has announced that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis.
"Obtaining orphan drug designation for Col-Treg in the European Union is a recognition of the therapeutic potential of Col-Treg in autoimmune uveitis. Whilst this is a rare disease, it is a leading cause of blindness in the developed world. TxCell estimates around 30,000 autoimmune uveitis patients per year in the US and EU alone, for whom existing treatments do not work, could benefit significantly from the development of Col-Treg," said Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell. "We are moving rapidly to undertake a placebo-controlled, dose-ranging proof of principle clinical study in autoimmune uveitis. This is planned to start in the first half of 2015. The top line results of this study are expected mid-2016."
Autoimmune uveitis is a debilitating inflammatory condition of the eye, often resulting in permanent vision damage. Uveitis is one of the leading causes of blindness in the developed world. It is a rare disease with a prevalence of around 35-50/100,000. Autoimmune uveitis constitutes 80-90 percent of cases.
No treatment is currently approved for the patients that become refractory to corticosteroid compounds. In addition, these products are known to cause serious side effects when used for a prolonged period. Because of the low safety and the increased resistance to existing drugs, the development of new and safer class of therapeutics to treat autoimmune uveitis is essential.
In the EU, the benefits of Orphan Drug Designation from the European Commission include protocol assistance and possible exemptions or reductions in regulatory fees during development. Another benefit from the classification is 10 years of market exclusivity from product launch.
“The achievement of these designations for Col-Treg, our second product candidate, is a result of the strength of TxCell’s ASTrIA platform to generate innovative personalized T cell immunotherapy treatments for severe autoimmune diseases. After moving Col-Treg into a first clinical study in the first half of 2015, TxCell will then look to pursue a streamlined development program towards the market, given the very significant need for new treatments for this severe disease,” said Damian Marron, CEO, TxCell. “TxCell will continue to push forward the Col-Treg program in addition to its lead product, Ovasave®, for which a phase IIb clinical in refractory Crohn’s disease was recently started, to bring novel solutions to patients in need and value to the whole community.”
Antimalarial Drugs Could Offer Clinical Benefit to Cancer PatientsNews
Antimalarial drugs chloroquine and hydroxychloroquine could find another use as cancer treatments, according to a new clinical study published in ecancermedicalscience.READ MORE
Chemists Design More Efficient Microreactor Using 3D PrintingNews
Researchers developed an electrochemical microreactor using additive manufacturing technology (commonly known as 3D printing). The newly developed microreactor was tested on synthesis of isoindolinones, which are found in many natural products, pharmaceuticals, and biologically active molecules.READ MORE
World’s Smallest Tape Recorder Is Built From MicrobesNews
Through a few clever molecular hacks, researchers at have converted a natural bacterial immune system into a microscopic data recorder, laying the groundwork for a new class of technologies that use bacterial cells for everything from disease diagnosis to environmental monitoring.